AACR Special Conference Dives Deep Into Tumor Immunology
Susan Kaech and Ton Schumacher gave thought-provoking keynotes at the AACR Special Conference: Tumor Immunology and Immunotherapy.
Related Articles
FDA approves revumenib for relapsed or refractory acute leukemia
On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.
Aligned Blog: Celebrating Native American Heritage Month: in conversation with Karina Walters, Ph.D., M.S.W.
To celebrate Native American Heritage Month, we spoke with Karina Walters, Ph.D., M.S.W., Director of the NIH Tribal Research Health Office (THRO). Dr. Walters, an…
Program
Explore the program for the AACR Special Conference in Cancer Research: Translating Targeted Therapies in Combination with Radiotherapy.
Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Oncology Pipeline: Exciting Breakthroughs Cited at AMCP Nexus 2024
Fully 1,600 cancer treatments and vaccines are in development, according to speakers at an AMCP Nexus 2024 presentation, in Las Vegas.
Let’s YAP about ITP
In this issue of Blood, Hu and colleagues show that reduced Yes-associated protein 1 (YAP1) expression in megakaryocytes (MK), via an impaired interaction
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
Key PointsOutcomes with single-agent gilteritinib across 38 National Health Service hospitals mirror those seen in clinical trials.Patients with adverse ka
Annual Meeting 2024 AACR Journals Concurrent Publications | American Association for Cancer Research
Annual Meeting 2024 AACR Journals Concurrent Publications | American Association for Cancer Research AACR Annual Meeting 2024: AACR Journals’ Concurrent Publications The AACR journal articles…
Genetics-Based Risk Model to Stratify Survival Outcomes of Patients With AML Treated With Venetoclax-Azacitidine | ASH Clinical News | American Society of Hematology
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. An analysis of treatment-naïve patients with acute myeloid leukemia (AML)…
SITC: Study Finds IO102-IO103 Vaccine Plus Pembrolizumab Active in Patients With Non–Small Cell Lung Cancer
To be presented at the 2024 Society for Immunotherapy of Cancer Annual Meeting, a phase II study by Riess et al investigating the IO102-IO103 vaccine…
